Nuvectis Pharma (NVCT) Cash from Operations (2021 - 2026)

Nuvectis Pharma has reported Cash from Operations for 6 years, with the latest figure at 6511000.0 in Q1 2026.

• Quarterly Cash from Operations fell 55.99% year-over-year to 6511000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 18346000.0 (down 52.08% YoY) and the FY2025 annual result came in at 16009000.0, down 30.72% from the prior year.
• Cash from Operations slipped to 6511000.0 in Q1 2026 per NVCT's latest filing, from 3974000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 2404000.0 in Q3 2024 and troughed at 6511000.0 in Q1 2026.
• A 5-year average of 3781176.47 and a median of 3850000.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations tumbled 229.52% in 2022, then soared 35.97% in 2024.
• Over 5 years, Cash from Operations stood at 3516000.0 in 2022, then declined by 9.5% to 3850000.0 in 2023, then surged by 35.97% to 2465000.0 in 2024, then sank by 61.22% to 3974000.0 in 2025, then tumbled by 63.84% to 6511000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 6511000.0, 3974000.0, and 4494000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.